ALBO - Albireo Pharma, Inc.
| Previous Close | 26.02 |
| Open | 25.92 |
| Bid | 21.03 x 1800 |
| Ask | 27.50 x 1300 |
| Day's Range | 23.79 - 25.92 |
| 52 Week Range | 19.10 - 38.69 |
| Volume | 64,246 |
| Avg. Volume | 59,690 |
| Market Cap | 301.91M |
| Beta (3Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.23 |
| Earnings Date | Dec 15, 2016 - Dec 19, 2016 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 55.14 |
Motley FoolAlbireo Pharma, Inc. (ALBO) Q2 2019 Earnings Call Transcript
ALBO earnings call for the period ending June 30, 2019.
- GlobeNewswire
Albireo Reports Second Quarter 2019 Financial Results
— Odevixibat Phase 3 PEDFIC 1 topline results expected mid-2020 —— Initiated elobixibat Phase 2 trial in NAFLD/NASH —— Management to host conference call and webcast today at 10.
- GlobeNewswire
Albireo to Present at Wedbush PacGrow Healthcare Conference
BOSTON, Aug. 06, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
- GlobeNewswire
Albireo to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast
BOSTON, Aug. 01, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
- Zacks
Analysts Estimate Albireo Pharma (ALBO) to Report a Decline in Earnings: What to Look Out for
Albireo Pharma (ALBO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Albireo Provides Mid-Year Clinical Development Update
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, provided an update on the progress of the development of odevixibat for pediatric cholestatic liver diseases and elobixibat for NASH. The odevixibat PEDFIC program in progressive familial intrahepatic cholestasis (PFIC) consists of two clinical trials.
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Albireo Pharma, Inc. (ALBO)
A market surge in the first quarter, spurred by easing global macroeconomic concerns and Powell's pivot ended up having a positive impact on the markets and many hedge funds as a result. The stocks of smaller companies which were especially hard hit during the fourth quarter slightly outperformed the market during the first quarter. Unfortunately, […]
- Simply Wall St.
Those Who Purchased Albireo Pharma (NASDAQ:ALBO) Shares A Year Ago Have A 11% Loss To Show For It
Albireo Pharma, Inc. (NASDAQ:ALBO) shareholders should be happy to see the share price up 13% in the last quarter. But...
- GlobeNewswire
Albireo Announces Launch of “PFIC Voices”
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the launch of PFIC Voices, a new global campaign to build awareness and understanding of the burden of progressive familial intrahepatic cholestasis (PFIC), an ultra-rare, genetic, pediatric liver disease. Through PFIC Voices, Albireo is joining with leaders from the patient advocacy community, families and clinicians to share perspectives about the impact of PFIC, and the critical need for education, treatment and support.
- GlobeNewswire
Data on Albireo’s Odevixibat Presented at 2019 European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that clinical data from a Phase 2 study of lead product candidate odevixibat (A4250), a highly potent and selective inhibitor of the ileal bile acid transporter (IBAT), in biliary atresia, Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC) were presented today at the 2019 European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting in Glasgow, Scotland.
- GlobeNewswire
Albireo to Present at Investor Conferences in June
BOSTON, May 29, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
- GlobeNewswire
Albireo Announces Data on Pediatric Cholestatic Liver Diseases to be Presented at the 2019 ESPGHAN Annual Meeting
BOSTON, May 23, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that.
Motley FoolAlbireo Pharma, Inc. (ALBO) Q1 2019 Earnings Call Transcript
ALBO earnings call for the period ending March 31, 2019.
- GlobeNewswire
Albireo to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast
BOSTON, May 02, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that.
- GlobeNewswire
Albireo Presents Data on A4250 in Children with Biliary Atresia and Alagille Syndrome at The International Liver Congress 2019
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that results in Alagille syndrome and biliary atresia patients from its completed Phase 2 clinical trial evaluating A4250 in pediatric cholestasis were presented at the European Association for the Study of the Liver (EASL) The International Liver Congress (ILC) 2019 in Vienna, Austria. “Liver damage caused by cholestasis is a hallmark of Alagille syndrome, a rare and life-threatening liver disease, and there is an urgent need for a non-invasive pharmacologic treatment option,” said Dr. Baumann, Professor of Pediatric Gastroenterology and Hepatology, Hannover Medical School in Hannover, Germany.
- GlobeNewswire
Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that its Investigational New Drug application (IND) has cleared the required 30 day review by the U.S. Food and Drug Administration and is in effect for a Phase 2 clinical trial of elobixibat, a first-in-class, once-daily, orally-available ileal bile acid transporter (IBAT) inhibitor, for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
- GlobeNewswire
Albireo to Present at Investor Conferences in April
BOSTON, April 01, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
- GlobeNewswire
Albireo to Present Clinical Data on A4250 in Alagille Syndrome and Biliary Atresia at The International Liver Congress™ 2019
BOSTON, March 27, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
- GlobeNewswire
Albireo Expands Executive Leadership Team with Appointment of Pamela Stephenson as Chief Commercial Officer
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the appointment of Pamela Stephenson, MPH, as Chief Commercial Officer, effective March 25, 2019. In the newly created leadership position, Stephenson will be responsible for overseeing the company’s commercial strategy and global commercial operations. “Albireo has entered the critical pre-commercial phase, as we prepare for results from our Phase 3 trial of A4250 in progressive familial intrahepatic cholestasis (PFIC),” said Ron Cooper, President and Chief Executive Officer of Albireo.
Motley FoolAlbireo Pharma, Inc. (ALBO) Q4 2018 Earnings Conference Call Transcript
ALBO earnings call for the period ending December 31, 2018.
- GlobeNewswire
Albireo Reports Year-End 2018 Financial Results and Provides Pipeline Update
- A4250 Phase 3 PFIC pivotal program on target for end of ‘19/early ’20 topline readout -- Plan to initiate second A4250 pivotal program in biliary atresia -- Plan to initiate.
- GlobeNewswire
Albireo to Present at Cowen and Company 39th Annual Health Care Conference
BOSTON, March 04, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
- GlobeNewswire
Albireo Recognizes Rare Disease Day and Highlights Urgent Need to Support Families Affected by Progressive Familial Intrahepatic Cholestasis (PFIC)
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced its support for Rare Disease Day, and reaffirmed its commitment to patients and families living with progressive familial intrahepatic cholestasis (PFIC) and other rare cholestatic liver diseases. “The medical need in PFIC is substantial,” said Ronald J. Sokol, MD, Professor and Vice Chair of Pediatrics, Children’s Hospital Colorado. PFIC is a severe, progressive, potentially life-threatening, ultra-rare liver disease characterized by pruritus (intense itching), jaundice (yellowing of the skin), and poor weight gain and growth.
- GlobeNewswire
Albireo to Report Year-End 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019
BOSTON, Feb. 27, 2019 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
